Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(14):1032-1033; doi:10.1093/jnci/95.14.1032
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twombly, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 14, 1032-1033, July 16, 2003
© 2003 Oxford University Press

NEWS

For Gene Therapy, Now-Quantified Risks Are Deemed Troubling

Renee Twombly

The first 150 words of the full text of this article appear below.

Just as the discovery of DNA turned 50, a gene therapy clinical trial in France became an example of what can be accomplished, as well as what might go wrong, when genetic material is used as medicine.

Earlier this year, several children with X-linked severe combined immunodeficiency disorder (X-SCID) developed leukemia after receiving treatment with gene therapy. Although effective, the treatment has not been used again after French officials halted the trial. In the United States, gene therapy trials that also use retroviral vectors were halted for a time in late January, and then restricted.

Now, a study from researchers at the National Human Genome Research Institute (NHGRI) may help explain how the vectors used play a role in cancer development in treated patients. They found that one popular retroviral vector, the murine leukemia virus (MLV), tends to insert genes into transcription "start regions" of the human genome. Those are . . . [Full Text of this Article]

The First Successful Gene Therapy

Future of MLV and Other Vectors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?